tiprankstipranks
Neurocrine price target raised to $150 from $140 at Citi
PremiumThe FlyNeurocrine price target raised to $150 from $140 at Citi
12d ago
Neurocrine price target raised to $164 from $154 at Canaccord
PremiumThe Fly
Neurocrine price target raised to $164 from $154 at Canaccord
13d ago
Neurocrine price target raised to $216 from $200 at Oppenheimer
PremiumThe Fly
Neurocrine price target raised to $216 from $200 at Oppenheimer
13d ago
Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
PremiumThe FlyNeurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
14d ago
Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
PremiumThe Fly
Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
14d ago
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
PremiumPress Releases
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
14d ago
Wells Fargo upgrades Neurocrine with pipeline ‘turning a corner’
PremiumThe FlyWells Fargo upgrades Neurocrine with pipeline ‘turning a corner’
21d ago
Neurocrine upgraded to Overweight from Equal Weight at Wells Fargo
PremiumThe Fly
Neurocrine upgraded to Overweight from Equal Weight at Wells Fargo
21d ago
Neurocrine NBI-1065845 results ‘look potentially promising,’ says RBC Capital
PremiumThe Fly
Neurocrine NBI-1065845 results ‘look potentially promising,’ says RBC Capital
22d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100